Literature DB >> 18337620

Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels.

Takahide Nakazawa1, Shigeru Adachi, Masashi Kitano, Yoshinori Isobe, Shigehiro Kokubu, Hisashi Hidaka, Koji Ono, Yusuke Okuwaki, Masaaki Watanabe, Akitaka Shibuya, Katsunori Saigenji.   

Abstract

OBJECTIVES: To examine the efficacy and prognostic benefits of radiotherapy (RT) in patients who have unresectable advanced hepatocellular carcinoma (HCC) with invasion to intrahepatic large vessels (IHLVs).
METHODS: Sixty-eight patients who had advanced HCC with invasion to IHLVs were studied. Thirty-two consecutive patients initially received 3-dimensional conformal RT for HCC invasion to IHLVs. Tumor response, prognostic factors, and survival were studied in the patients given RT. Prognostic factors and survival were assessed in the study group as a whole. Data were analyzed using the Kaplan-Meier method, univariate analysis, and a Cox model.
RESULTS: The rate of objective response to RT was 48%. Predictors of survival in the patients who received RT were a hepatic function of Child-Pugh class A (p = 0.0263) and a response to RT (p = 0.0121). In the study group as a whole, independent predictors of survival in a Cox model were multinodular HCC (p = 0.007), inferior vena caval invasion (p = 0.001), a serum alpha-fetoprotein level of >1,000 ng/ml (p = 0.032), and the performance of RT (p < 0.001). Notably, the median survival of the nonresponders to RT (n = 15) was significantly longer than that of the patients who received no treatment for HCC (n = 21; 7.0 vs. 3.4 months, p = 0.0014).
CONCLUSION: RT is considered an effective initial treatment for HCC invasion to IHLVs, and may offer survival benefits, even in nonresponders, because of the induction of stable disease. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2008        PMID: 18337620     DOI: 10.1159/000120996

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  18 in total

1.  Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report.

Authors:  Yusuke Okuwaki; Takahide Nakazawa; Hisashi Hidaka; Akitaka Shibuya; Wasaburo Koizumi
Journal:  J Med Case Rep       Date:  2012-01-26

Review 2.  Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review.

Authors:  Kichang Han; Jin Hyoung Kim; Gi-Young Ko; Dong Il Gwon; Kyu-Bo Sung
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 4.  Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus.

Authors:  Tianfu Wen; Chen Jin; Antonio Facciorusso; Matteo Donadon; Ho-Seong Han; Yilei Mao; Chaoliu Dai; Shuqun Cheng; Bixiang Zhang; Baogang Peng; Shunda Du; Changjun Jia; Feng Xu; Jie Shi; Juxian Sun; Peng Zhu; Satoshi Nara; J Michael Millis
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

Review 5.  Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.

Authors:  Kichang Han; Jin Hyoung Kim
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

6.  Long-term surviving patient with inferior vena cava tumor thrombus and extrahepatic metastasis after spontaneous ruptured hepatocellular carcinoma.

Authors:  Kensaku Sanefuji; Kengo Fukuzawa; Masahiro Okamoto; Seiichiro Kai; Hajime Takaki; Yonemasu Hirotoshi; Akira Motohiro; Kenzo Wakasugi
Journal:  Clin J Gastroenterol       Date:  2011-02-15

Review 7.  Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Dong Soo Lee; Jinsil Seong
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

8.  Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib - a report of two cases.

Authors:  Takahide Nakazawa; Hisashi Hidaka; Akitaka Shibuya; Wasaburo Koizumi
Journal:  Case Rep Oncol       Date:  2010-08-12

9.  Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis.

Authors:  Mian Xi; Li Zhang; Lei Zhao; Qiao-Qiao Li; Su-Ping Guo; Zi-Zhen Feng; Xiao-Wu Deng; Xiao-Yan Huang; Meng-Zhong Liu
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

10.  Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.

Authors:  Jing Chen; Chengya Zhou; Yu Long; Xude Yin
Journal:  Tumour Biol       Date:  2014-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.